| pubmed-article:20737169 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20737169 | lifeskim:mentions | umls-concept:C0699791 | lld:lifeskim |
| pubmed-article:20737169 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:20737169 | lifeskim:mentions | umls-concept:C0282523 | lld:lifeskim |
| pubmed-article:20737169 | lifeskim:mentions | umls-concept:C2348519 | lld:lifeskim |
| pubmed-article:20737169 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20737169 | pubmed:dateCreated | 2010-10-4 | lld:pubmed |
| pubmed-article:20737169 | pubmed:abstractText | Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n?=?10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study. | lld:pubmed |
| pubmed-article:20737169 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20737169 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20737169 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20737169 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20737169 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:20737169 | pubmed:issn | 1432-2307 | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:KimTae-YouTY | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:KangGyeong... | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:ChoNam-YunNY | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:KimYoung... | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:KookMyeong... | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:ParkSeog-YunS... | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:KwonHyeong-Ju... | lld:pubmed |
| pubmed-article:20737169 | pubmed:author | pubmed-author:JungNamheeN | lld:pubmed |
| pubmed-article:20737169 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20737169 | pubmed:volume | 457 | lld:pubmed |
| pubmed-article:20737169 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20737169 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20737169 | pubmed:pagination | 415-22 | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:meshHeading | pubmed-meshheading:20737169... | lld:pubmed |
| pubmed-article:20737169 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20737169 | pubmed:articleTitle | CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. | lld:pubmed |
| pubmed-article:20737169 | pubmed:affiliation | Department of Pathology, National Cancer Center, Goyang, Gyeonggi-do, South Korea. | lld:pubmed |
| pubmed-article:20737169 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20737169 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
